, Tracking Stock Market Picks
Enter Symbol:
Biomarin Pharmaceutical Inc. (BMRN) [hlAlert]

down 6.18 %

Biomarin Pharmaceutical Inc. (BMRN) rated Buy with price target $156 by Deutsche Bank

Posted on: Thursday,  Jun 18, 2015  12:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) on 06/18/2015, when the stock price was $139.52. Since
then, Biomarin Pharmaceutical Inc. has lost 6.19% as of 11/25/2015's recent price of $130.89.
If you would have followed this Deutsche Bank's recommendation on BMRN, you would have lost 6.18% of your investment in 160 days.

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/18/2015 12:25 PM Buy
139.52 156.00
as of 8/27/2015
1 Week down  -2.20 %
1 Month down  -5.73 %
3 Months up  6.71 %
1 YTD down  -6.18 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/14/2014 2:25 PM Buy
70.97 85.00
3/20/2013 1:25 PM Hold
61.18 59.00
8/27/2012 1:25 PM Hold
38.09 45.00
9/28/2011 12:25 PM Buy
32.96 40.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy